<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               7  DRUG INTERACTIONS<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                        <BR>                           <BR>                              Monoamine Oxidase Inhibitors. (4.2,<BR>                                  7.1)<BR>                              <BR>                           <BR>                           <BR>                              CYP2D6 Inhibitors – Concomitant use may increase atomoxetine steady–state plasma concentrations in EMs. (7.2)<BR>                              <BR>                           <BR>                           <BR>                              Pressor Agents – Possible effects on blood<BR>pressure. (7.3)<BR>                              <BR>                           <BR>                           <BR>                              Albuterol (or other beta2 agonists)– Action of albuterol on cardiovascular system can be potentiated. (7.4)<BR>                              <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     7.1  Monoamine Oxidase Inhibitors<BR>                     <BR>                        With other drugs that affect brain monoamine<BR>concentrations, there have been reports of serious, sometimes fatal reactions<BR>(including hyperthermia, rigidity, myoclonus, autonomic instability with possible<BR>rapid fluctuations of vital signs, and mental status changes that include<BR>extreme agitation progressing to delirium and coma) when taken in combination<BR>with an MAOI. Some cases presented with features resembling neuroleptic malignant<BR>syndrome. Such reactions may occur when these drugs are given concurrently<BR>or in close proximity <BR>                              [see Contraindications (4.2)]<BR>                           .<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     7.2  Effect of CYP2D6 Inhibitors on Atomoxetine<BR>                     <BR>                        In extensive metabolizers (EMs), inhibitors of<BR>CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady–state<BR>plasma concentrations to exposures similar to those observed in poor metabolizers<BR>(PMs). In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is<BR>approximately 6– to 8–fold and<BR>Css,max is about 3– to 4–fold<BR>greater than atomoxetine alone.<BR>                        In vitro studies suggest that<BR>coadministration of cytochrome P450 inhibitors to PMs will<BR>not increase the plasma concentrations of atomoxetine.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     7.3  Pressor Agents<BR>                     <BR>                        Because of possible effects on blood pressure, STRATTERA should<BR>be used cautiously with pressor agents (e.g., dopamine, dobutamine).<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     7.4  Albuterol<BR>                     <BR>                        STRATTERA should<BR>be administered with caution to patients being treated with systemically–administered<BR>(oral or intravenous) albuterol (or other beta2 agonists)<BR>because the action of albuterol on the cardiovascular system can be potentiated<BR>resulting in increases in heart rate and blood pressure. Albuterol (600 mcg iv<BR>over 2 hours) induced increases in heart rate and blood pressure.<BR>These effects were potentiated by atomoxetine (60 mg BID for 5 days) and were most marked<BR>after the initial coadministration of albuterol and atomoxetine.<BR>However, these effects on heart rate and blood pressure were not seen in another<BR>study after the coadministration with inhaled dose of albuterol (200-800 mcg)<BR>and atomoxetine (80 mg QD for 5 days) in 21 healthy Asian subjects who were<BR>excluded for poor metabolizer status.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     7.5  Effect of Atomoxetine on P450 Enzymes<BR>                     <BR>                        Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450<BR>enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9.<BR>                        <BR>                           CYP3A Substrate<BR>(e.g., Midazolam) — Coadministration of STRATTERA (60 mg<BR>BID for 12 days) with midazolam, a model compound for CYP3A4<BR>metabolized drugs (single dose of 5 mg), resulted in 15%<BR>increase in AUC of midazolam. No dose adjustment is recommended for drugs<BR>metabolized by CYP3A.<BR>                        <BR>                           CYP2D6<BR>Substrate (e.g., Desipramine) — Coadministration of STRATTERA (40 or<BR>60 mg BID for 13 days) with desipramine,<BR>a model compound for CYP2D6 metabolized drugs (single dose of 50 mg),<BR>did not alter the pharmacokinetics of desipramine. No dose adjustment is recommended<BR>for drugs metabolized by CYP2D6.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     7.6  Alcohol<BR>                     <BR>                        Consumption of ethanol with STRATTERA did<BR>not change the intoxicating effects of ethanol.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     7.7  Methylphenidate<BR>                     <BR>                        Coadministration of methylphenidate with STRATTERA did<BR>not increase cardiovascular effects beyond those seen with methylphenidate<BR>alone.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     7.8  Drugs Highly Bound to Plasma Protein<BR>                     <BR>                        In vitro drug–displacement<BR>studies were conducted with atomoxetine and other highly–bound drugs at therapeutic concentrations. Atomoxetine did<BR>not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam<BR>to human albumin. Similarly, these compounds did not affect the binding of atomoxetine to<BR>human albumin.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     7.9  Drugs that Affect Gastric pH<BR>                     <BR>                        Drugs that elevate gastric pH<BR>(magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on STRATTERA bioavailability.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>